Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb
19.5.2021 11:00:00 EEST | Business Wire | Press release
Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY). This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia’s portfolio of shared assets. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology & immunology. The agreement includes up to $50 million in upfront funding, up to $125 million in near to mid-term potential milestones, and additional clinical, regulatory and commercial payments that take the potential value of the deal beyond $1.2 billion. Exscientia will also receive tiered royalties on net sales of any marketed drug products resulting from the collaboration.
This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in 2019 with Celgene prior to Celgene’s acquisition by Bristol Myers Squibb. Exscientia will take responsibility for AI-design and experimental work necessary to discover drug candidates associated with this collaboration for Bristol Myers Squibb. Molecules will be designed using Exscientia’s AI-driven drug discovery platform, which delivers optimized compounds fulfilling complex design goals faster and more effectively than traditional drug discovery.
Andrew Hopkins, CEO of Exscientia, commented, “We are proud that Bristol Myers Squibb wants to build on our work together with this expanded collaboration and believe it speaks to the strength and promise of Exscientia’s AI technologies and drug discovery expertise. We’re excited to work with such an experienced collaborator as Bristol Myers Squibb to develop the best possible medicines for patients.”
Rupert Vessey, President of Research & Early Development at Bristol Myers Squibb said, “We have been pleased with Exscientia’s work in tackling a number of distinct projects for Bristol Myers Squibb. Exscientia’s application of AI technologies is proving capable of generating best-in-class molecules while also reducing discovery times. Rapid discovery of molecules that can enter the clinic in a timely manner could positively impact our work in discovering treatments for areas of unmet medical need”
Exscientia has already built a strong track record for its drug discovery platform, being the first company to advance AI-designed small molecule drug candidates into clinical studies. In addition to Bristol Myers Squibb, Exscientia has previously entered collaborations with major pharmaceutical companies including Bayer, Sanofi, and Dainippon Sumitomo, multiple emerging biotech companies and the Gates Foundation, demonstrating Exscientia’s reputation as the collaborator of choice for high-value AI-driven drug discovery. The company currently has more than a dozen partnered or wholly owned drugs in development. Exscientia recently secured a $525 million Series D investment, led by Softbank, to further fund expansion of its technology capabilities and proprietary drug pipeline.
About Exscientia
Exscientia’s AI centric, end-to-end drug discovery platform is set to revolutionise the process invention of new drugs, designing therapeutics for areas of high unmet medical need that could positively impact patients, with timelines that are many years shorter than industry standards. As a clinical stage company, Exscientia is the first to advance AI-designed small molecules into a clinical setting, demonstrating the potential of AI to transform the pharmaceutical industry.
Drug design is precision engineering at the molecular scale. To transform the industry, Exscientia has built dedicated AI systems that efficiently learn from the widest range of data and consistently re-apply enhanced knowledge through iterations of design. Because Exscientia’s AI systems learn more rapidly and effectively than human-led efforts, candidate molecules satisfying complex therapeutic requirements are discovered with revolutionary efficiency.
For more information visit us on www.exscientia.ai or follow us on Twitter @exscientiaAI.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210519005180/en/
Contact information
PR Contacts:
Edelman PR:
Anitra Sprauten
P: +44 (0)78 9685 9386
Anitra.Sprauten@edelman.com
Stephanie Crisp
P: +44 (0)75 8300 3417
stephanie.crisp@edelman.com
For Exscientia
Mark Swindells, Chief Commercial Officer
contact@exscientia.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
GenNx360 Capital Partners Closes Fourth Flagship Fund at $865 Million27.8.2026 15:30:00 EEST | Press release
GenNx360 Capital Partners (“GenNx360” or “the Firm”), a New York City-based private equity firm investing in U.S. lower middle market industrial services and business services companies, today announced the successful closing of GenNx360 Capital Partners IV, L.P. (“Fund IV” or “the Fund”), with $865 million in commitments, exceeding its target. Fund IV is the largest fund raised in GenNx360’s history. Fund IV was supported by a diverse group of existing and new investors including leading pensions, asset managers, insurance companies, foundations, and family offices, reflecting conviction in the firm’s disciplined investment approach, operational value creation model, and tenured, diverse team. Fund IV will continue GenNx360’s differentiated strategy of partnering with lower middle market founders and management teams to scale essential services businesses. Fund IV has made five investments to date across infrastructure services, testing and inspection services, aerospace and defense,
Alipay Ant Forest Turns 700 Million Users’ Daily Green Actions into 700 Million Trees Over a Decade of Technology-enabled Environmental Program27.8.2026 15:02:00 EEST | Press release
Alipay Ant Forest, Ant Group’s green initiative that encourages people to participate in environmental protection through simple, everyday low-carbon actions, today announced that more than 700 million users across China have joined the program as of August 2026. Together, they have helped support the planting of over 700 million trees, contributing to ecological restoration efforts in some of China’s most arid and environmentally fragile regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827995848/en/ Before (2019) and after (2026) comparison of Ant Forest Project No. 464 in Inner Mongolia. Launched in 2016 within the Alipay app, Ant Forest transforms individual environmental choices into collective climate action. When users make greener lifestyle choices, such as taking public transportation, cycling, paying bills online to avoid paper invoices, or choosing digital services, they earn virtual “green energy points”
Omilia Appoints Michael Weiss as Vice President, DACH27.8.2026 15:00:00 EEST | Press release
Omilia, a global leader in Self-Learning Agentic CX, today announced the appointment of Michael Weiss as Vice President, DACH. Weiss will lead Omilia's go-to-market strategy across Germany, Austria, and Switzerland, as the company expands its European footprint, with a focus on regulated sectors where enterprise demand for AI that moves past pilot-stage containment is accelerating. In his new role, Weiss will be responsible for enterprise sales, partner development, and go-to-market execution across DACH, building the team and customer relationships needed to scale Omilia's presence in a market where large, heavily regulated enterprises have historically been slow to move off legacy IVR and first-generation AI. Weiss brings more than two decades of enterprise sales leadership in SaaS, cloud, and customer experience (CX) technology. Most recently, he provided fractional Chief Revenue Officer services through his own advisory practice where he advised CX and cloud communications provider
Visa Expands Support for its Clients and the Industry as Organizations Navigate New AI Era of Cybersecurity27.8.2026 15:00:00 EEST | Press release
Visa (NYSE: V) today announced enhancements to its cybersecurity portfolio to help organizations identify and fix vulnerabilities more effectively. Unveiling the next evolution of the Visa Vulnerability Agentic Harness (VVAH), its open-source, model-agnostic framework, Visa is helping organizations significantly reduce the Mean Time to Adapt (MTTA), the time between discovery and resolution of attack paths, with some resolutions shrinking from weeks to hours. And to help clients navigate this evolving threat landscape, Visa also announced the expansion of its Visa Consulting & Analytics (VCA) Cybersecurity Advisory Practice with new advisory services designed to help clients assess risk, prioritize remediation efforts and strengthen resilience in an evolving threat environment. "AI is compressing the time between vulnerability discovery and exploitation, which means defenders need a faster, more reliable path to action," said Rajat Taneja, President, Technology, Visa. "By advancing VVA
Perma-Pipe Announces Closing of Global Credit Facility of Up to $139 Million27.8.2026 14:47:00 EEST | Press release
Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH) (“Perma-Pipe” or the “Company”), a leading global provider of engineered piping and leak detection solutions for energy, infrastructure and industrial markets, today announced the closing of a new global credit facility with J.P. Morgan consists of a $75.0 million revolving credit facility and a $14.0 million term loan facility, and allows the Company access to an additional $50.0 million in incremental capacity. The new facility replaces and consolidates multiple existing credit facilities maintained by the Company and its subsidiaries across various jurisdictions, creating a more streamlined and centralized financing structure for Perma-Pipe’s global operations. It also provides Perma-Pipe with significantly increased financial capacity, enhanced liquidity and greater flexibility to support working capital requirements, letters of credit, strategic investments and the Company’s continued expansion in key markets. Saleh Sagr, Pres
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom